GLPwatch
Papers (12034)
Page 39 of 201, ranked by citation count.
- C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.
- Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
- Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
- Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
- Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
- GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.
- Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
- GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.
- Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
- Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
- Human embryonic stem cell differentiation into insulin secreting β-cells for diabetes.
- Recent advancements in drug treatment of obesity.
- Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats.
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
- Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways.
- Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
- Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.
- Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.
- Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
- The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.
- Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes.
- High fat diet and GLP-1 drugs induce pancreatic injury in mice.
- Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.
- A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
- Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway.
- Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.
- Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
- Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function.
- Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
- Comparative studies on the influences of primary emulsion preparation on properties of uniform-sized exenatide-loaded PLGA microspheres.
- Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
- Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.
- Obesity pharmacotherapy: incretin action in the central nervous system.
- Genetically Encoded Cholesterol-Modified Polypeptides.
- Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1).
- Current Drug Targets in Obesity Pharmacotherapy - A Review.
- Liraglutide protects pancreatic β-cells against free fatty acids in vitro and affects glucolipid metabolism in apolipoprotein E-/- mice by activating autophagy.
- After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
- The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers.
- In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent.
- Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
- Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
- Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ.
- Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
- Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice.
- GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis.
- Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation.
- Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
- The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity.
- Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.
- GLP-1 Agonists in Type 1 Diabetes Mellitus.
- Weight-centric treatment of type 2 diabetes mellitus.
- The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
- Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action.
- Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa.